Report copyright - Clinuvel Pharmaceuticals - ASX · Clinuvel Pharmaceuticals Ltd – Consolidated Entity - A.B.N 88 089 644 119 4 Target Indications Erythropoietic protoporphyria (EPP) is a rare metabolic
Please pass captcha verification before submit form